Sumatriptan
If you find any inaccurate information, please let us know by providing your feedback here

This article is compiled based on the United States Pharmacopeia (USP) – 2025 Edition
Issued and maintained by the United States Pharmacopeial Convention (USP)
C14H21N3O2S 295.40
1H-Indole-5-methanesulfonamide, 3-[2-(dimethylamino) ethyl]-N-methyl-;
3-[2-(Dimethylamino)ethyl]-N-methyl-1H-indole-5- methanesulfonamide CAS RN®: 103628-46-2; UNII: 8R78F6L9VO.
1 DEFINITION
Sumatriptan contains NLT 98.0% and NMT 102.0% of sumatriptan (C14H21N3O2S), calculated on the anhydrous and solvent-free basis.
2 IDENTIFICATION
Change to read:
A. Spectroscopic Identification Tests 〈197〉, Infrared Spectroscopy: 197M (CN 1-May-2020)
B. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.
3 ASSAY
Procedure
Diluent: Dissolve 3.9 g of monobasic sodium phosphate dihydrate in water. Adjust with a solution of 50% (w/v) sodium hydroxide to a pH of about 6.5, and dilute with water to 1 L. Mix 750 mL of the this solution with 250 mL of acetonitrile.
Buffer: Dissolve 1.7 mL of dibutylamine, 0.6 mL of phosphoric acid, and 3.9 g of monobasic sodium phosphate dihydrate in water. Adjust with a solution of 50% (w/v) sodium hydroxide to a pH of about 6.5, and dilute with water to 1 L.
Mobile phase: Acetonitrile and Buffer (25:75)
System suitability solution: 0.28 mg/mL of USP Sumatriptan Succinate RS and 0.14 mg/mL of USP Sumatriptan Succinate Related
Compound C RS in Diluent
Standard solution: 0.14 mg/mL of USP Sumatriptan Succinate RS in Diluent
Sample solution: 0.1 mg/mL of Sumatriptan in Diluent
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 282 nm
Column: 4.6-mm × 25-cm; 5-μm packing L1
Flow rate: 1.5 mL/min
Injection volume: 10 μL
System suitability
Samples: System suitability solution and Standard solution
[Note—The relative retention times for sumatriptan succinate related compound C and sumatriptan are 0.9 and 1.0, respectively.]
Suitability requirements
Resolution: NLT 1.5 between sumatriptan succinate related compound C and sumatriptan, System suitability solution
Relative standard deviation: NMT 1.5%, Standard solution
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of sumatriptan (C14H21N3O2S) in the portion of the sample taken:
Result = (rU /rS ) × (CS /CU ) × (Mr1/Mr2 ) × 100
rU = peak response from the Sample solution
rS = peak response from the Standard solution
CS = concentration of USP Sumatriptan Succinate RS in the Standard solution (mg/mL)
CU = concentration of Sumatriptan in the Sample solution (mg/mL)
Mr1 = molecular weight of sumatriptan, 295.4
Mr2 = molecular weight of sumatriptan succinate, 413.5
Acceptance criteria: 98.0%–102.0% on the anhydrous and solvent-free basis
4 IMPURITIES
Procedure 1: Limit of Sumatriptan Related Compound A
Buffer: Dissolve 77.1 g of ammonium acetate in 100 mL of water.
Mobile phase: Methanol and Buffer (90:10)
Standard solution: 6.25 μg/mL of USP Sumatriptan Succinate Related Compound A RS in Mobile phase
Sample solution: 2 mg/mL of Sumatriptan in Mobile phase
Chromatographic system
(See Chromatography 〈621〉, System Suitability.)
Mode: LC
Detector: UV 282 nm
Column: 4.6-mm × 25-cm; 5-μm packing L3
Flow rate: 2 mL/min
Injection volume: 20 μL
System suitability
Sample: Standard solution
Suitability requirements
Relative standard deviation: NMT 5%
Analysis
Samples: Standard solution and Sample solution
Calculate the percentage of sumatriptan related compound A in the portion of Sumatriptan taken:
Result = (rU /rS ) × (CS /CU ) × (Mr1/Mr2 ) × 100
rU = peak response from the Sample solution
rS = peak response from the Standard solution
CS = concentration of USP Sumatriptan Succinate Related Compound A RS in the Standard solution (mg/mL)
CU = concentration of Sumatriptan in the Sample solution (mg/mL)
Mr1 = molecular weight of sumatriptan related compound A, 495.7
Mr2 = molecular weight of sumatriptan succinate related compound A, 613.8
Acceptance criteria: NMT 0.6%
Procedure 2
Diluent and System suitability solution: Prepare as directed in the Assay.
Buffer: Dissolve 1.7 mL of dibutylamine, 0.6 mL of phosphoric acid, and 3.9 g of monobasic sodium phosphate dihydrate in water. Adjust with a solution of 50% (w/v) sodium hydroxide to a pH of about 7.5, and dilute with water to 1 L.
Mobile phase: Acetonitrile and Buffer (25:75)
Identification solution: 3 mg/mL of USP Sumatriptan Succinate Related Impurities RS in Mobile phase
Sample solution: 2 mg/mL of Sumatriptan in Diluent
Chromatographic system: Prepare as directed in the Assay. After making sure that the resolution criteria are met, chromatograph the
Identification solution, and record the peak responses as directed in the Analysis. Identify the peaks according to Table 1.
System suitability
Sample: System suitability solution
Suitability requirements
Resolution: NLT 1.5 between sumatriptan succinate related compound C and sumatriptan
Analysis
Sample: Sample solution
Calculate the percentage of each impurity in the portion of Sumatriptan taken:
Result = (rU/rT) × 100
rU = peak response for each impurity
rT = sum of all the peak responses
Acceptance criteria: See Table 1.
Table 1
| Name | Relative Retention Time | Acceptance Criteria, NMT (%) |
|---|---|---|
| [3-[2-(Dimethylamino-N-oxide)ethyl]-1H-indol-5-yl]- N-methylmethanesulfonamide | 0.3 | 0.2 |
| [3-[2-(Aminoethyl)]-1H-indol-5-yl]-N-methylmethanesulfonamide | 0.4 | 0.1 |
| [3-[2-(Methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide | 0.6 | 0.5 |
| Sumatriptan succinate related compound C | 0.9 | 0.5 |
| Sumatriptan | 1.0 | – |
| Any individual unspecified impurity | – | 0.1 |
| Total impuritiesa | – | 1.5 |
a Includes the amount of sumatriptan related compound A determined in the test for Limit of Sumatriptan Related Compound A.
5 SPECIFIC TESTS
Water Determination, Method I 〈921〉: NMT 1.0%
6 ADDITIONAL REQUIREMENTS
Packaging and Storage: Preserve in tight, light-resistant containers. Protect from freezing, and store below 30°.
Change to read:
USP Reference Standards 〈11〉
USP Sumatriptan RS
USP Sumatriptan Succinate RS
USP Sumatriptan Succinate Related Compound A RS
[3-[2-(Dimethylamino)ethyl]-2-[[3-[2-(dimethylamino) ethyl]-1H-indol-5-yl]methyl]-1H-indol-5-yl]-N-methylmethanesulfonamide succinate salt.
C14H21N3O2S · C4H6O4 613.77
USP Sumatriptan Succinate Related Compound C RS
[3-[2-(Dimethylamino)ethyl]-1-(hydroxymethyl)-1H-indol-5-yl]-N-methylmethanesulfonamide succinate salt.
C15H23N3O3S · 0.5C4H6O4 384.47
USP Sumatriptan Succinate Related Impurities RS
Mixture of sumatriptan succinate, [3-[2-(methylamino)ethyl]-1H-indol-5-yl]-N-methylmethanesulfonamide, (ERR 1-Jun-2019) sumatriptan succinate related compound C, [3-[2-(dimethylamino-N-oxide)ethyl]-1H-indol- 5-yl]-N-methylmethanesulfonamide, and [3-[2-(aminoethyl)]-1H- indol-5-yl]-N-methyl methanesulfonamide.

